Clinical Use of Ruxolitinib in an Academic Medical Center in Unselected Patients With Myeloproliferative Neoplasms not on Clinical Study

Ruxolitinib is the only approved therapy for myelofibrosis. However, its use in patients with myeloproliferative neoplasms not participating in clinical studies has been poorly described. The researchers reviewed the medical records of 45 patients and found ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate). 

 Leuk Lymphoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.